Previous 10 |
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Cowen and C...
CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, t...
CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the 8th Annual L...
CORAL GABLES, FL / ACCESSWIRE / February 6, 2019 / The biotech stock market has always been a sector replete with innovation, and conversation surrounding companies looking into nuanced approaches to designing effective treatment options for patients suffering a wide array of diseases. Acc...
Gainers: MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi...
News, Short Squeeze, Breakout and More Instantly...
Neon Therapeutics Inc. Company Name:
NTGN Stock Symbol:
NASDAQ Market:
Neon Therapeutics Inc. Website:
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN) today announced the acceptance of its Clinical Trial Authorization (CTA) from the Dutch Health Authority (DHA) for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01. Neon...
BNT111 FixVac Melanoma registrational trial start planned for 2H 2020 BNT121 (iNeST) adjuvant Phase 2 study in NSCLC to start in 2H 2020 COVID-19 vaccine program BNT162 set to enter the clinic in April 2020 Ended 2019 with cash equivalents of $583 million ( €520 millio...
NEW YORK, NY / ACCESSWIRE / February 13, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Forescout Technologies, Inc. (NASDAQ: FSCT )...